Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease

E-ISSN： 1875-6212|8|6|849-860

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.8, Iss.6, 2010-11, pp. : 849-860

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting MCP-1 to Reduce Vascular Complications of Obesity

Recent Patents on Cardiovascular Drug Discovery, Vol. 4, Iss. 3, 2009-11 ,pp. : 164-176

Bentham Science Publishers

Access to resources Recommend Favorite

Diabetic kidney disease: new treatment options

By Thomas Merlin C

Diabetes Management, Vol. 3, Iss. 2, 2013-03 ,pp. : 123-130

Future Medicine

Access to resources Recommend Favorite

The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease

Current Diabetes Reviews, Vol. 11, Iss. 3, 2015-09 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System

Current Diabetes Reviews, Vol. 4, Iss. 1, 2008-02 ,pp. : 63-78

Bentham Science Publishers

Access to resources Recommend Favorite

Pathophysiological Role of Growth Factors in Diabetic Kidney Disease: Focus on Innovative Therapy

By Flyvbjerg A. Hill C. Logan A.

Trends in Endocrinology and Metabolism, Vol. 10, Iss. 7, 1999-09 ,pp. : 267-272

Elsevier

Access to resources Recommend Favorite